Anti-lipid phospate phosphohydrolase-3 (LPP3) antibody inhibits bFGF- and VEGF-induced capillary morphogenesis of endothelial cells

Cell Communication and Signaling

Volumn 3, Issue , 2005, Pages

  Wary, Kishore K ^a   Humtsoe, Joseph O ^a,b  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

bFGF; Capillary morphogenesis; Collagen matrices; Endothelial cells; VCIP; VEGF

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CELL SURFACE PROTEIN; COLLAGEN TYPE 1; EPITOPE; LIPID PHOSPHATE PHOSPHOHYDROLASE 3 PROTEIN; LIPID PHOSPHATE PHOSPHOHYDROLASE 3 PROTEIN ANTIBODY; PROTEIN ANTIBODY; PROTEIN LPP3; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CAPILLARY PROLIFERATION; CELL ACTIVATION; CELL SURFACE; CONTROLLED STUDY; ENDOTHELIUM CELL; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; TUMOR VASCULARIZATION; UPREGULATION; VASCULAR ENDOTHELIUM;

EID: 33646587935     PISSN: 1478811X     EISSN: None     Source Type: Journal    
DOI: 10.1186/1478-811X-3-9     Document Type: Article

References (42)

1. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31.
2. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
3. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997, 8:4-25.
4. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
5. Sato Y, Kanno S, Oda N, Abe M, Ito M, Shitara K, Shibuya M: Properties of two VEGF receptors, FIt-I and KDR, in signal transduction. Ann N Y Acad Sci 2000, 902:201-205.
6. Ferrara N: Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001, 280:C1358-1366.
7. Werb Z: ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997, 91:439-442.
8. Shapiro SD: Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol 1998, 10:602-608.
9. Wary KK: Molecular targets for anti-angiogenic therapy. Curr Opin Mol Ther 2004, 6:54-70.
10. Varner JA, Cheresh DA: Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Important Adv Oncol 1996:69-87.
11. Varner JA: The role of vascular cell integrins alpha v beta 3 and alpha v beta 5 in angiogenesis. EXS 1997, 79:361-390.
12. Eliceiri BP, Cheresh DA: The role of alpha v integrins during angiogenesis. Mol Med 1998, 4:741-750.
13. Ruoslahti E, Engvall E: Integrins and vascular extracellular matrix assembly. J Clin Invest 1997, 100:S53-56.
14. Elicieri BP, Cheresh DA: Alphav beta3 integrin and its antagonists in the control of angiogenesis. In Tumor angiogenesis and Microcirculation Edited by: Emile E Voest, Patricia A Damore. Mercel Dekker, Inc, New York City, NY, 2001:387-398.
15. Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell 2000, 110:673-687.
16. Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992, 69:11-25.
17. Wary KK, Mainiero F, Isakoff SJ, Marcantonio EE, Giancotti FG: The adaptor protein Shc couples a class of integrins to the control of cell cycle progression. Cell 1996, 87:733-743.
18. Wary KK, Mariotti A, Zurzolo C, Giancotti FG: A requirement for caveolin-I and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell 1998, 94:625-634.
19. Guan JL: Focal adhesion kinase in integrin signaling. Matrix Biol 1997, 16:195-200.
20. Assoian RX, Marcantonio EE: The extracellular matrix as a cell cycle control element in atherosclerosis and restenosis. J Clin Invest 1996, 98:2436-2439.
21. Giancotti FG, Ruoslahti E: Integrin signaling. Science 1999, 285:1028-1032.
22. Stupack DG, Cheresh DA: Integrins and angiogenesis. Curr Top Dev Biol 2004, 64:207-238.
23. Humtsoe JO, Feng S, Thakker GD, Yang J, Hong J, Wary KK: Regulation of cell-cell interactions by phosphatidic acid phosphatase 2b/VCIP. EMBO J 2003, 22:1539-1554.
24. Wary KK, Thakker GD, Humtsoe JO, Yang J: Analysis of VEGF-responsive Genes Involved in the activation of endothelial cells. Mol Cancer 2003, 2:1-12.
25. Brindley DN: Lipid phosphate phosphatases and related proteins: signaling functions in development, cell division, and cancer. J Cell Biochem 2004, 92:900-912.
26. Saba JD: Lysophospholipids in development: Miles apart and edging in. J Cell Biochem 2004, 92:967-992.
27. Siess W, Tigyi G: Thrombogenic and atherogenic activities of lysophosphatidic acid. J Cell Biochem 2004, 92:1086-1094.
28. Humtsoe JO, Bowling RA, Feng S, Wary KK: Murine Lipid phosphate phosphohydrolase acts as a cell associated integrin ligand. Biochem Biophys Res Commun in press.
29. Kai M, Wada I, Imai S, Sakane F, Kanoh H: Identification and cDNA cloning of 35-kDa phosphatidic acid phosphatase (type 2) bound to plasma membranes. J Biol Chem 1996, 271:18931-18938.
30. Roberts R, Sciorra VA, Morris AJ: Human type 2 phosphatidic acid phosphohydrolases: substrate specificity of the type 2a, 2b and 2c enzymes and cell surface activity of the 2a isoform. J Biol Chem 1998, 273:22059-22067.
31. Sciorra VA, Morris AJ: Sequential actions of phospholipase D and phosphatidic acid phosphohydrolase 2b generate diglyceride in mammalian cells. Mol Biol Cell 1999, 10:3863-3876.
32. Ishikawa T, Kai M, Wada I, Kanoh H: Cell surface activities of the human type 2b phosphatidic acid phosphatase. J Biochem (Tokyo) 2000, 127:645-651.
33. Jia YJ, Kai M, Wada I, Sakane F, Kanoh H: Differential localization of lipid phosphate phosphatases 1 and 3 to cell surface subdomains in polarized MDCK cells. FEBS Lett 2003, 552:240-246.
34. Zhang N, Sundberg JP, Gridley T: Mice mutant for Ppap2c, a homolog of the germ cell migration regulator wunen, are viable and fertile. Genesis 2000, 27:137-140.
35. Escalante-Alcalde D, Hernandez L, Le Stunff H, Maeda R, Lee HS, Cheng Gang Jr, Sciorra VA, Daar I, Spiegel S, Morris AJ, Stewart CL: The lipid phosphatase LPP3 regulates extra-embryonic vasculogenesis and axis patterning. Development 2003, 130:4623-4637.
36. Humtsoe JO, Kim JK, Xu Y, Keene DR, Höök M, Lukomski S, Wary KK: A streptococcal collagen-like protein interacts with the alpha2betal integrin and induces intracellular signaling. J Biol Chem 2005, 280:13848-13857.
37. Bayless KJ, Salazar R, Davis GE: RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. Am J Pathol 2000, 156:1673-1683.
38. Bell SE, Mavila A, Salazar R, Bayless KJ, Kanagala S, Maxwell SA, Davis GE: Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. J Cell Sci 2001, 114:2755-7273.
39. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-571.
40. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-1164.
41. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA: Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995, 270:1500-1502.
42. Matter ML, Ruoslahti E: A signaling pathway from the alpha5beta1 and alpha(v)beta3 integrins that elevates bcl-2 transcription. J Biol Chem 2001, 276:27757-27763.